INSIGHTS ON ENTERPRISE SOLUTIONS
-
![Cytiva Bio]( "Designing ADC Manufacturing For Operator And Patient Safety")
Designing ADC Manufacturing For Operator And Patient SafetyADC manufacturing succeeds when manufacturability is treated as an early design input. Cell line choices, toxic payload handling, and single-use extractables each shape operator exposure and risk.
-
![Millipore bio]( "Designing A Single-Use ADC Production Suite")
Designing A Single-Use ADC Production SuiteDedicated antibody-drug conjugate production inside a fixed footprint and timeline depends on single-use workflow design that balances conjugation flexibility, primary containment, and fluid management.
-
![Charter Medical Bio]( "Advancing Downstream Bioprocessing With Single-Use Solutions")
Advancing Downstream Bioprocessing With Single-Use SolutionsClosed, configurable single-use fluid management between downstream steps can influence how flexible, efficient, and agile a bioprocess is, from early development through commercial production.
-
![GettyImages-1089913166-scientist-glasses-laboratory-research]( "Why Process Efficiency & Expertise Outweigh Capacity")
Why Process Efficiency & Expertise Outweigh CapacityFacility expansion alone doesn't ensure commercial success. Operational efficiency, team alignment, and technical expertise are equally critical.
-
Designing, Selecting, And Developing Bioconjugates For Clinical Success11/5/2026
Accelerate the development of complex bioconjugates to unlock new possibilities for targeted therapies and advance the next generation of precision medicine.
-
How Automation Can Facilitate Annex 1 Compliance In Final Filtration11/3/2026
Annex 1 expectations for PUPSIT expose how much risk sits in operator-dependent final filtration, and why automation, assembly design, and product recovery now shape compliance decisions.
-
Cytovance Capabilities Update October 2026: Large Molecule11/3/2026
Move biologics from research and development toward commercialization with integrated development, analytics, scalable GMP manufacturing, and early-phase fill-finish capabilities.
-
Simtra Biopharma Solutions Capabilities Update October 2026: Fill Finish11/3/2026
Explore new sterile manufacturing capacity for pre-filled syringes, lyophilized vials, and potent therapies, supporting flexibility, scale, and supply resilience.
ENTERPRISE SOLUTIONS
-
![GettyImages-1324475324 Lab]( "Nanomedicine: Where Few CDMOs Dare To Go")
Custom nanoparticle development and cGMP manufacturing for medical applications are specialized work that few contract partners attempt, spanning the path from preclinical studies to commercialization.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "We Know NANO: Our Expertise")
A single partner carries nanomedicine programs from screening to clinical supply across lipid, polymeric, and metal-based particles, with precursor manufacturing newly added to the lineup.
-
![Lab Experiment-GettyImages-158649166]( "Small-Scale Studies To Support Preclinical Viral Vector Development")
Small-scale AAV and LV batches let programs test constructs and generate IND-enabling data on guaranteed timelines, with a defined route from feasibility work toward eventual GMP production.
-
![GettyImages-586165998-scientists-inspecting-contamination]( "Complex ADC Development. Simplified. One Coordinated European Platform")
Successful targeted oncology programs combine biological engineering, potent compound synthesis, and efficient manufacturing to reduce complexity and speed clinical progress.
-
![10]( "Your Partner In Biosimilar Success")
Bringing biosimilars to market efficiently requires strong cell line development, analytical characterization, and scalable manufacturing backed by regulatory expertise.
